Ovid Therapeutics Inc. · NASDAQ:OVID

Ovid Therapeutics — Technical Presentation (October 2020)

68 slides from Ovid Therapeutics's technical presentation, Oct 22, 2020

  1. Slide 1: Angelman Syndrome & OV101 (gaboxadol) Seminar

    Angelman Syndrome & OV101 (gaboxadol) Seminar October 22, 2020 October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Exhibit 99.1

  2. Slide 2: Disclaimers and Forward-Looking Statements

    Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “believe,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expre

  3. Slide 3: Welcome

    Welcome Jeremy Levin, DPhil, MB, BChir Chairman & Chief Executive Officer Ovid Therapeutics October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

  4. Slide 4: Today's Speakers

    Jason Tardio MBA Amit Rakhit MD, MBA Judith Jaeger PhD, MPA Christopher Keary MD Matthew During MD, DSc, FACP, FRACP Jeremy Levin DPhil, MB, BChir Chief Commercial Officer President & Chief Medical Officer President & Principal Scientist Child, Adolescent & Adult Psychiatrist Founder, Ovid SAB Chair

  5. Slide 5: Agenda

    Patient-Centric Approach To Commercializing OV101 OV101 in Angelman Syndrome, Clinical Results, What to Expect from NEPTUNE The Importance of Clinical Global Impression of Improvement (CGI-I) Treating a Patient with Angelman Syndrome Tonic Inhibition, Angelman Syndrome and OV101 Welcome and Introduc

  6. Slide 6: Ovid's Rich Pipeline Focused on Rare Neurological Diseases

    Ovid’s Rich Pipeline Focused on Rare Neurological Diseases PRODUCT CANDIDATE INDICATION RESEARCH PRECLINICAL PHASE 1 PHASE 2 PHASE 3 OV101 δ-selective GABAA receptor agonist Angelman Syndrome Fragile X OV935 CH24H inhibitor CDKL5 Deficiency Disorder / Dup15q Syndrome Dravet LGS OV329 GABA aminotrans

  7. Slide 7: Defining the Therapeutic Landscape for Angelman Syndrome

    Defining the Therapeutic Landscape for Angelman Syndrome ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED October 22, 2020 Partnership and Potential for Rare Disease Voucher, Multiple Sources of Future Capital Patent Protection Through 2035 Extensive Safety and Tolerability Database No Other Appro

  8. Slide 8: Conquering Angelman Syndrome: The Beginning

    Conquering Angelman Syndrome: The Beginning * https://www.angelman.org/about/history/ October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1965* 1987 Angelman Syndrome Described Unravelling the Role of Tonic Inhibition Begins Genetic Defect Identified ü ü ü 2012

  9. Slide 9: Conquering Angelman Syndrome: A Pivotal Moment

    Conquering Angelman Syndrome: A Pivotal Moment * https://www.angelman.org/about/history/ October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1965* 1987 2014 Angelman Syndrome Described Unravelling the Role of Tonic Inhibition Begins Genetic Defect Identified Ovid Identifies Key Link

  10. Slide 10: Conquering Angelman Syndrome: Laying the Foundation

    Conquering Angelman Syndrome: Laying the Foundation * https://www.angelman.org/about/history/ October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1965* 1987 2014 2015-16 Angelman Syndrome Described Unravelling the Role of Tonic Inhibition Begins Genetic Defect Identified Ovid Identif

  11. Slide 11: Conquering Angelman Syndrome: Proof of Concept

    Conquering Angelman Syndrome: Proof of Concept * https://www.angelman.org/about/history/ October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1965* 1987 2014 2015-16 2018 Angelman Syndrome Described Unravelling the Role of Tonic Inhibition Begins Genetic Defect Identified Ovid Identif

  12. Slide 12: Conquering Angelman Syndrome: The Next Step

    Conquering Angelman Syndrome: The Next Step * https://www.angelman.org/about/history/ October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1965* 1987 2014 2015-16 2018 Q4 2020 Angelman Syndrome Described Unravelling the Role of Tonic Inhibition Begins Genetic Defect Identified Ovid Id

  13. Slide 13: Caregiver quote

    “I thought I would have to teach my child about the world. It turns out, I have to teach the world about my child.” - AS CAREGIVER October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

  14. Slide 14: Tonic Inhibition, Angelman Syndrome and OV101

    Tonic Inhibition, Angelman Syndrome and OV101 Matt During, M.D. DSc, FACP, FRACP Founder, Ovid Therapeutics Chairman, Scientific Advisory Board, Ovid Therapeutics October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

  15. Slide 15: Bringing tonic inhibition from the lab to the patient

    Bringing tonic inhibition from the lab to the patient OV101 would be the first selective, extrasynaptic GABAA receptor agonist for any indication October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

  16. Slide 16: GABA is an Essential Neurotransmitter in The Brain

    CNS=central nervous system; E/I=excitatory/inhibitory; GABA=γ-aminobutyric acid. 1. Chebib M, Johnston GA. Clin Exp Pharmacol Physiol. 1999;26:937-940. 2. Bannai H et al. Cell Rep. 2015;13:2768-2780. 3. Whissell PD et al. Neuropharmacology. 2015;88:24-35. 4. Wu C, Sun D. Metab Brain Dis. 2015;30:367

  17. Slide 17: Genetic Defects in Angelman Syndrome Can Disrupt GABA Signaling

    Deficient UBE3A1 Decreased tonic inhibition1,3,4 Decreased tonic inhibition causes the brain to become inundated with excitatory signals resulting in a wide range of symptoms1,3,4 Decreased extrasynaptic GABA1,3,4 Increased GABA reuptake1,3,4 Genetic Defects in Angelman Syndrome Can Disrupt GABA Sig

  18. Slide 18: Extrasynaptic GABA Signaling Mediates Tonic Inhibition

    Extrasynaptic GABA Signaling Mediates Tonic Inhibition—the Brain’s Ability To Distinguish Signal From Noise Information Available to the Brain at Low, Optimal, and Excessive Levels of Tonic Inhibition4,5 GABA=γ-aminobutyric acid. 1. Brickley SG, Mody I. Neuron. 2012;73:23-34. 2. Egawa K et al. Sci T

  19. Slide 19: Tonic Inhibition Regulates Distinct Functions Based on Location

    Tonic inhibition Regulates Distinct Functions Based on Location in The Brain1-4 Tonic inhibition in the hippocampus and amygdala regulates memory processes and anxiety-like behaviors2 Tonic inhibition in the cortex is associated with cognitive behavior such as object recognition2 Tonic inhibition in

  20. Slide 20: OV101 Restores Tonic Inhibition in Angelman Syndrome

    OV101 Restores Tonic Inhibition in Angelman Syndrome (AS) Which May Normalize Core Functions UBE3A, ubiquitin protein ligase E3A; GABA, ɣ-aminobutyric acid. HEALTHY ANGELMAN SYNDROME GABA Production GABA Transporter GABA δ Synaptic GABAAR OV101 Presynaptic Neuron Post-synaptic Neuron Extrasynaptic G

  21. Slide 21: Optimal Level of Tonic Inhibition Required for Normal Neuronal Function

    Optimal Level of Tonic Inhibition Required for Normal Neuronal Function 1. Adapted from Duguid et al., J. Neuroscience, 2012. 2. Adapted from Egazwa et al., Science Translational Medicine, 2012 October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

  22. Slide 22: Preclinical Proof-of-Concept in Angelman Syndrome

    Preclinical Proof-of-Concept in Angelman Syndrome Effect on Posture, Movement and Gait Animal model for AS well characterized UBE3A gene-knockout mouse model Replicates impaired motor function of AS In AS mouse model, OV101: Restored tonic inhibition in cerebellar cells Corrected motor phenotype Imp

  23. Slide 23: OV101 Mechanism Summary

    OV101 Extrasynaptic δ subunit containing GABAA receptors are responsible for tonic inhibition and set the overall tone or sensitivity of the system to ensure optimal signal to noise ratio over time OV101 is a highly selective δ subunit GABAA receptor agonist OV101 has a unique mechanism with greates

  24. Slide 24: Treating a Patient With AS

    Treating a Patient With AS Christopher Keary, MD Child, Adolescent and Adult Psychiatrist Assistant in Psychiatry, Lurie Center Mass General Hospital for Children October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

  25. Slide 25: Angelman Syndrome: An Overview

    Angelman Syndrome: An Overview Angelman syndrome is a complex genetic disorder with no approved therapies No approved therapies since condition first described in 1965 Disease results from loss of functional UBE3A protein due to defect of UBE3A gene on maternal chromosome 151,2 Decreased extrasynapt

  26. Slide 26: Neurological Dysregulation in Angelman Syndrome Results in Significant Impairments

    Neurological Dysregulation in Angelman Syndrome Results in Significant Impairments Behavior Heightened hyperactivity and anxiety can result in maladaptive behaviors, such as biting and pinching1,2 Sleep Increased nighttime awakenings and diminished total sleep time1 Learning Impaired cognitive perfo

  27. Slide 27: Angelman Syndrome: High Unmet Medical Need

    Angelman Syndrome: High Unmet Medical Need Caregiver and Family Burden: Lifelong around-the-clock supervision needed Life- Limiting Features of AS 24-Hr Care Required for Life Reduced Leisure Activities and Socialization Time Frequent Medical Appointments Stress, Anxiety, Depression Need for Support

  28. Slide 28: Quotes From Caregivers

    October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Quotes From Caregivers “It’s a full-time job for his family and teachers. He can never be out of our sight for even an instant. It’s too dangerous for him.” Mom, 14 y/o son with AS “ “I’m so tired of having to educate my daughter’s

  29. Slide 29: Treatment Paradigm: No Approved Therapy For Angelman Syndrome

    Treatment Paradigm: No Approved Therapy For Angelman Syndrome 81% of patients take multiple concomitant off label drugs, only addressing individual symptoms with limited success3-6 and adverse reactions specific to AS Pharmacological Treatment Unmet Need Behavior Hyperactivity: psychostimulants (met

  30. Slide 30: Management of AS is Currently Limited to Supportive Care

    Management of AS is Currently Limited to Supportive Care Following diagnosis, families are often referred to specialists, therapists and specialized school programs However, behavioral challenges such as aggression and hyperactivity can significantly delay and limit improvement with these therapies

  31. Slide 31: Individuals with Angelman Syndrome Require Continual Support From Caregivers

    Individuals with Angelman Syndrome Require Continual Support From Caregivers Increasing Stress, Anxiety and Exhaustion Individuals with AS have very little independence even in adulthood1,2 AS individuals require continued and lifelong support from caregivers4,5 Caring for AS individuals affects mat

  32. Slide 32: Challenges When Transitioning to Adulthood for Patients with AS

    Even More Challenges Arise When Transitioning to Adulthood for Patients with AS and Their Caregivers Loss of access to care (speech, behavior and physical therapies) Limited availability of structures to address the specific needs of adults with AS and treat the heterogeneity of disease manifestatio

  33. Slide 33: OV101: A Treatment with the Potential to Impact the Entire Brain

    OV101: A Treatment with the Potential to Impact the Entire Brain ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED October 22, 2020 OV101 (gaboxadol) is a highly selective oral extrasynaptic GABA receptor agonist, which works to improve signaling regulation throughout the entire brain It is propose

  34. Slide 34: CGI-I-AS in Angelman Syndrome

    CGI-I-AS in Angelman Syndrome Judith Jaeger, PhD President and Principal Scientist CognitionMetrics LLC October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

  35. Slide 35: CGI in History

    CGI in History CGI was developed in the 1970s to provide a brief, stand-alone assessment of the clinician's view of the patient's global functioning prior to and after initiating a clinical trial medication1 Since its first publication, CGI has become one of the most widely used assessment tools in

  36. Slide 36: History of CGI in Pharmaceutical Development

    History of CGI in Pharmaceutical Development Since the inception of clinical psychopharmacology, measuring treatment effects was accomplished with validated disease specific rating scales. However regulators and clinicians worried about whether total scores were the most meaningful metric CGI was de

  37. Slide 37: CGI is Optimal Endpoint for Angelman Syndrome

    CGI is Optimal Endpoint for Angelman Syndrome Use of CGI as the primary trial endpoint is optimal in: Rare disorders that lack validated disease-specific rating scales (Validation process takes years and many subjects) Conditions with large phenotypic heterogeneity (including Angelman syndrome) CGI-

  38. Slide 38: CGI-I in Angelman Syndrome: Improvement Determines Therapeutic Effect

    CGI-I in Angelman Syndrome: Improvement Determines Therapeutic Effect Each person with AS is unique - AS manifests differently in each patient (e.g. variation in relative severity of behavior, communication, motor dysfunction etc.) CGI-S provides a valid and reliable global measure of baseline disea

  39. Slide 39: How is CGI-I-AS used?

    How is CGI-I-AS used? CGI-I-AS is used to measure a patient’s symptom change since starting treatment across four key clinical areas of Angelman syndrome CGI-I-AS can be used to measure clinical improvement or worsening after starting a therapy Communication Motor What is CGI-I? The Clinical Global

  40. Slide 40: Establishing the Baseline: CGI-S-AS

    Establishing the Baseline: Clinical Global Impression of Severity in Angelman Syndrome (CGI-S-AS) ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED October 22, 2020 Example: Motor Domain Domain Severity = 1 Severity = 2 Severity = 3 Severity = 4 Severity = 5 Severity = 6 Severity = 7 Motor Normal,

  41. Slide 41: Rating Change from Baseline: CGI-I-AS

    Rating Change from Baseline: Clinical Global Impression of Improvement in Angelman Syndrome (CGI-I-AS) ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED October 22, 2020 Example: Motor Domain Motor Record observations (all sources) List clinical symptom(s) that have Improved or Worsened since basel

  42. Slide 42: Clinical Global Impressions-Improvement – Angelman Syndrome (CGI-I-AS)

    Clinical Global Impressions-Improvement – Angelman Syndrome (CGI-I-AS) ***Use this form in conjunction with the CGI-I-AS Investigator Notes form CGI-I-AS Score Clinical Criteria 1 = Very much improved Marked improvement, likely affecting multiple symptoms Changes likely visible in multiple settings

  43. Slide 43: CGI-I-AS: Ratings

    CGI-I-AS: Ratings ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED October 22, 2020 KEY IMPROVEMENT METRICS Clinical Responder Non-Responder 01 02 03 04 05 06 07 Absence of change or worsening overall Clinically meaningful improvement overall Mean Improvement Responder Analysis Odds Ratio ü ü ü

  44. Slide 44: What Measured Change Means For Patients and Families

    What Measured Change Means For Patients and Families Physician and parent observations illustrating CGI-I from STARS trial “She could, for the first time, help with activities of daily living like undressing, she independently went to the fridge to obtain the medicine, it was unconceivable before th

  45. Slide 45: OV101 in Angelman Syndrome

    OV101 in Angelman Syndrome Amit Rakhit, MD, MBA President and Chief Medical Officer October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

  46. Slide 46: OV101 Registrational Plan in Angelman Syndrome

    OV101 Registrational Plan in Angelman Syndrome ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED October 22, 2020 Registration Package STARS Phase 2 Study Completed in Q3’18 NEPTUNE Phase 3 Enrollment Complete ELARA Open Label Extension Study Started in Q1’19

  47. Slide 47: STARS Phase 2 Clinical Trial Established the First Approvable Endpoint

    Outcome Measures Primary Outcome Measure: Safety and tolerability of OV101 vs placebo Prespecified Efficacy Measures: CGI-I, sleep, behavior, motor Exploratory Efficacy Measures Trial Design and Key Inclusion Criteria 88 adults and adolescents 12 sites in US, 1 site in Israel Age 13–49 years, inclus

  48. Slide 48: STARS Trial Achieved Clinically and Statistically Meaningful Change in CGI-I

    Phase 2 STARS Trial Achieved a Clinically and Statistically Meaningful Change in CGI-I ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED October 22, 2020 Mean CGI-I change from baseline of 0.79 vs placebo (P=0.0006). 74% of Study Responders on OV101 QD Experienced Clinical Improvement in Multiple D

  49. Slide 49: STARS: 3x more Patients on OV101 QD Reported Improvement

    Phase 2 STARS Trial: 3x more Patients on OV101 QD Reported Improvement on CGI-I vs Placebo1 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1. Responder analysis from the QD patient arm of STARS study n=27. October 22, 2020 3x Higher vs Placebo

  50. Slide 50: Summary of Safety and Tolerability Findings

    Summary of Safety and Tolerability Findings ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED October 22, 2020 OV101 Achieved Primary Endpoint of Safety and Tolerability as measured by incidence of AEs Overall favorable risk profile and well tolerated Similar incidence of AEs across all treatment a

  51. Slide 51: STARS Achieved Both Safety and Efficacy Endpoints

    Phase 2 STARS Trial: Achieved Both Safety and Efficacy Endpoints; Provided Foundation for Phase 3 Study Design ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED October 22, 2020 OV101 QD achieved a statistically significant improvement in CGI-I at Week 12 vs placebo (P=0.0006) STARS demonstrated cl

  52. Slide 52: NEPTUNE – Pivotal Phase 3 Study in Angelman Syndrome

    Objectives Primary endpoint: CGI-I-AS at Week 12 of OV101 vs placebo Secondary endpoints: Sleep measures Vineland Adaptive Behavior Scale 3rd edition Change in CGI-S-AS Trial Design Randomized, double-blind, Phase 3 study Up to 15 sites in United States, Israel, Australia, Netherlands and Germany Ap

  53. Slide 53: NEPTUNE Data Readout Planned For Q4'20

    NEPTUNE Data Readout Planned For Q4’20 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED October 22, 2020 NEPTUNE key outcomes: Changes in CGI-I-AS compared to placebo Responder analysis and magnitude of response for OV101 vs. placebo Efficacy across multiple domains including sleep, behavior, moto

  54. Slide 54: ELARA – Phase 3, Open Label Extension Study

    Objectives Primary endpoint: Long-term safety and tolerability as assessed by incidence and severity of AEs and SAEs Secondary endpoints: Long-term efficacy in global functioning, sleep, motor, behavior and quality-of-life Long term safety as assessed by vital signs, suicidality, laboratory assessme

  55. Slide 55: Favorable Results in Q4 Inform Next Steps

    Favorable Results in Q4 Inform Next Steps ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED October 22, 2020 NEPTUNE Dataset to Be the Basis of a Comprehensive Registrational Package Regulatory Designations Rare Pediatric Disease designation; eligible for pediatric voucher (if OV101 is approved) Fa

  56. Slide 56: Patient-Centric Approach To Commercializing OV101

    Patient-Centric Approach To Commercializing OV101 Jason Tardio Chief Commercial Officer Ovid Therapeutics October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

  57. Slide 57: Five Critical Areas of Focus

    Patient-Centric Approach To Commercializing OV101: Five Critical Areas of Focus ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Engagement with the Angelman Syndrome Advocacy Community Gaining Insights About Their Journey & Impact of Disease Designing Medicines, Clinical Trials & Outcomes To Meet

  58. Slide 58: Angelman Syndrome Affects Approximately 1 in 15,000 Individuals Worldwide

    Angelman Syndrome Affects Approximately 1 in 15,000 Individuals Worldwide Sources: 1. Angelman Syndrome Foundation Website: https://www.angelman.org/what-is-as/ Estimated Prevalence of Angelman Syndrome Worldwide1 ~500k patients October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

  59. Slide 59: The Worldwide AS Advocacy Community is Active and Mobilized

    The Worldwide AS Advocacy Community is Active and Mobilized An Active and Mobilized Worldwide AS Advocacy Community October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

  60. Slide 60: The Impact of AS on the Individual and Family/Caregiver

    The Impact of AS on the Individual and Family/Caregiver is Significant Reduced Leisure Activities and Socialization Time Stress, Anxiety, Depression Financial Strain and Reduced Work Capacity Siblings reported more sibling rivalry Increased arguments with spouses or partners High levels of fatigue C

  61. Slide 61: Clinical symptoms reflect functional deficits across multiple domains

    Clinical symptoms reflect functional deficits across multiple domains Seizure Motor control and gait Speech and communication Sleep Behavior and affect GI and feeding issues Current Symptomatic Therapies Non-specific to AS: Anti-Epileptics Anxiolytics Melatonin Antipsychotics Proton Pump Inhibitors

  62. Slide 62: If Approved, OV101 Would Be the First AS-specific Treatment

    OV101 (gaboxadol) Disrupted Inhibition/Excitation Balance Disrupted GABAergic function Changes in other molecular markers Lack of normal circuitry, etc. Clinical symptoms reflect functional deficits across multiple domains Seizure Motor control and gait Speech and communication Sleep Behavior and af

  63. Slide 63: First Mover Advantage

    First Mover Advantage: OV101 Will Lay the Foundation for AS-Specific Therapies and Will Help to Establish Ovid as the Leader in This Space ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED October 22, 2020 Gene Therapy Improve Synaptic Function Activate Paternal UBE3A Improve Tonic Inhibition DISCO

  64. Slide 64: Global Commercial Strategy: Partner Ex-US; Go Alone in US

    US Ovid Therapeutics plans to commercialize OV101 in the United States Europe Angelini Pharma has obtained exclusive rights to OV101 for the potential treatment of Angelman syndrome in the European Union, United Kingdom, Switzerland, Turkey, Russia and other countries in the European Economic Area C

  65. Slide 65: Disease State Awareness & No-Cost Genetic Testing Program

    Disease State Awareness & No-Cost Genetic Testing Program To Launch in 2021 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Increase Access to Genetic Testing Offer a simple, effective and no-cost genetic testing program Improving accurate diagnosis Up to 50% of individuals with Angelman syndrome

  66. Slide 66: Commercial Summary

    Commercial Summary ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED October 22, 2020 The Angelman Syndrome community is large (~500,000 patients), well-organized and actively engaged There are significant needs in the areas of motor functioning, communication, behavior, and sleep for individuals w

  67. Slide 67: Fireside Chat and Q&A

    Jason Tardio MBA Amit Rakhit MD, MBA Judith Jaeger PhD, MPA Christopher Keary MD Matthew During MD, DSc, FACP, FRACP Jeremy Levin DPhil, MB, BChir Chief Commercial Officer President & Chief Medical Officer President & Principal Scientist Child, Adolescent & Adult Psychiatrist Founder, Ovid SAB Chair

  68. Slide 68: Thank You

    Thank You October 22, 2020 ©2020 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

Ovid Therapeutics — Technical Presentation (October 2020) on 6ix